Journal List > J Korean Diabetes Assoc > v.30(1) > 1062413

Hong, Lee, Park, Kim, Nam, and Kim: The Percent Change of Body Weight in Patients with Type 2 Diabetes Using Rosiglitazone for 1 Year

Abstract

Background

Rosiglitazone(RSG) is known as a potent agonist for the PPARγ. It improves glycemic control by improving insulin sensitivity in peripheral tissues. And it is associated with body weight gain. The Pro12Ala polymorphism of the gene encoding the peroxisome proliferator-activated receptor(PPAR)γ2 has recently been shown to be associated with insulin sensitivity. This study was performed to evaluate the body weight change during the long term rosiglitazone treatment and the role of PPARγ2 polymorphism, Pro12Ala as an indicator to predict the clinical response of RSG in type 2 diabetes patients.

Methods

The study subjects were 214 type 2 diabetic patients(117 male, 97 female) who were received a daily 1 year course of 4 mg RSG combined with sulfonylurea or metformin. The Pro12Ala polymorphism of the PPARγ2 was determined by the restriction fragment length polymorphism(RFLP) method. Body weight, height, waist circumference, fasting glucose, insulin, c-peptide and lipid profile were measured.

Results

After RSG treatment, body weight change was 2.4±3.8%, 4.5±9.8% of baseline body weight at 12, 24 weeks respectively. Body weight gains were increased to 5.6±10.1% at the end of 1 year. The HbA1C, serum insulin level and HOMA index were decreased following the rosiglitazone therapy. The allele frequency of the Ala12Pro polymorphism of the PPARγ2 was 0.016. The number of Ala12Pro variant of the PPARγ2 was too low to predict clinical response of RSG. Body weight gain was correlated with basal fasting plasma glucose, post-prandial 2 hour glucose and HbA1c level(p<0.05). There was no correlation between baseline body weight and change.

Conclusion

This results showed that Pro12Ala polymorphism was not acceptable for the predictor of RSG induced weight gain and clinical response. However, body weight gain was increased in who had high glucose level, and correlated positively with glucose decrease. 1st 3 month weight gain was best predictor of weight change during 1 year.

Figures and Tables

Table 1
Baseline characteristics
jkda-30-47-i001

Data are given as means ± SD.

PP2hG: postprandial 2 hour glucose

Table 2
Clinical changes of the subjects
jkda-30-47-i002

Data are given as mean ± SD.

*p<0.05 vs basal

Table 3
Clinical findings by PPARγ2 polymorphism
jkda-30-47-i003

Data are given as mean ± SD. PP2hG: postprandial 2 hour glucose

Table 4
Weight change according the initial 3 month weight gain change
jkda-30-47-i004

Data are given as mean ± SD(%change body weight), bwt: body weight

*p<0.05 vs basal body weight.

References

1. Spigelman BM. PPAR-γ, adipogenic regulator and thiazolidinedine receptor. Diabetes. 1998. 47:507–514.
2. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999. 22:908–912.
3. Day C. Thiazolidinediones: new class of antidiabetic drugs. Diabet Med. 1999. 16:179–192.
4. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Digail I, Morin J, Auwerx J, Ferre P. Pioglitazone induce in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 1997. 46:1393–1399.
5. Shimizu H, Tsuchyiya T, Sato N, Shimomura Y, Kobauashi I, Mori M. Troglitazone reduce plasma leptin concentration but increase hunger in NIDDM patients. Diabetes Care. 1998. 21:1470–1474.
6. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther. 2000. 22:1151–1168.
7. Stumvoll M, Hἅring H. The peroxisome proliferator-activated receptorγ2 Pro12Ala polymorphism. Diabetes. 2002. 51:2341–2347.
8. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J. The peroxisome proliferator-activated receptor γ2 Pro12Ala variant: association with type 2 diabetes and trait differences. Diabetes. 2001. 50:886–890.
9. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPAR gamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998. 20:284–287.
10. Lei HH, Chen MH, Yang WS, CHiu MC, Chen MC, Tai TY, Cjuang LM. Peroxisome prolifereator-activated receptor gamma 2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism. 2000. 49:1267–1270.
11. Kuzuya T, Kosaka K, Akanuma Y, Shigeta Y, Kaneko T. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with NIDDM. Diabets Res Clin Pract. 1998. 41:121–129.
12. Lindi V, Sivenius K, Niskanen L, Laskos M, Uusitupa MI. Effect of the Pro12Ala polymorphism of the PPAR gamma2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia. 2001. 44:925–926.
14. Akazawa S, Kawasaki E, Sun F, Eguchi K, Ito M. Efficacy of troglitazone on body fat distribution type 2 diabetes. Diabetes Care. 2000. 23:1067–1071.
15. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism. 2005. 54:24–32.
17. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inxucchi SE, Shulman GI, Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002. 51:797–802.
18. Altshuler D, Hirchhorn JN, Klannemark M, Lindgren CM, Vohl M-C, Nemesh J, Lane CD, Schaffner SF, Bolk A, Brewer C, Tuomi T, Vaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Gen. 2000. 26:76–80.
19. Oh EY, Min KM, Chung JH, MIn YK, Lee MS, Kim KW, Lee MK. Significance of Pro12Ala mutation in Peroxisome Proliferator-Activated Receptor γ2 in Korean diabetic and Obese Subjects. J Clin Endocrinol Metab. 2000. 85:1801–1807.
21. Stumvoll M, Wahl HS, Löblein K, Becker R, Machicao F, Jacob S, Hἅring H. Pro12Ala polymorphism in the peroxosome proliferator-activated receptor2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes. 2001. 50:876–881.
22. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso A. Two polymorphism in the peroxisome proliferator-activated receptor gene are associated with severe overweight among obese women. J Clin Endocrinol Metb. 1999. 84:3708–3712.
TOOLS
Similar articles